FibroGen Q3 revenue up 15% to $46.3M; net loss narrows to $17.1M; reiterates FY guidance

KYNTRA BIO, INC.

2024-Q3 EPS reported -$0.66 revenue$152,877,000

Net product revenue from roxadustat in China $46.2M, +57% YoY; total roxadustat net sales $96.6M, +25% YoY.
Net loss $17.1M ($0.17 loss per share) vs $63.6M ($0.65) YoY; cash & equivalents $160M sufficient into 2026.
Full-year guidance: total roxadustat net sales $330-350M; net product revenue $135-150M; cost plan substantially complete by year-end.
Pamrevlumab trials in pancreatic cancer (mPDAC and LAPC) failed primary endpoints; pipeline focus shifts to FG-3246 ADC.
FG-3246 Phase 2 combo study results expected 1H 2025; Phase 2 monotherapy trial starts Q1 2025; CIA approval decision early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.